Biote Reports Fourth Quarter and Full Year 2022 Financial Results

Rhea-AI Summary

Biote (NASDAQ: BTMD) announced strong financial results for Q4 and the full year 2022, achieving record revenue of $165.0 million and a 24.6% increase in Adjusted EBITDA to $50.1 million. The Q4 revenue rose 18.5% to $44.5 million, supported by a 40% increase in Adjusted EBITDA to $13.1 million. Despite a net income of $1.3 million, the company reported an operating loss of $60.7 million due to substantial stock compensation and transaction-related expenses. For 2023, Biote anticipates revenue between $190-$200 million and Adjusted EBITDA of $56-$60 million, reflecting a continued focus on growth and market expansion.

Positive

• Q4 revenue increased by 18.5% year over year to $44.5 million.
• Adjusted EBITDA for Q4 rose 40% to $13.1 million.
• Full year 2022 revenue was up 18.3% from 2021, reaching $165.0 million.
• Adjusted EBITDA for full year 2022 increased by 24.6% to $50.1 million.
• Strong Q4 performance positions Biote for growth in 2023 with guidance of $190-$200 million in revenue.

Negative

• The company reported a significant operating loss of $60.7 million for 2022, primarily due to stock compensation and transaction costs.
• Net income for 2022 fell to $1.3 million, down from $32.6 million the previous year.

Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022

Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million

Significantly Increased Trading Liquidity with Recent Successful Secondary Offering

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Fourth Quarter Highlights, year over year:

• Revenue of $44.5 million, an 18.5% increase.
• Net income of $12.8 million and fully diluted GAAP earnings per share of $0.18.
• Adjusted EBITDA of $13.1 million, a 40% increase.¹

Full Year 2022 Highlights, year over year:

• Revenue of $165.0 million, an 18.3% increase.
• Net income of $1.3 million and fully diluted GAAP loss per share of $(0.12).
• Adjusted EBITDA of $50.1 million, up 24.6%.²
• Continued to execute growth strategy to capture large market opportunity for both providers and patients

“Biote achieved record financial results in the fourth quarter and for the full 2022 year, driven by strong growth in revenue and Adjusted EBITDA, which were at the high end of our guidance,” said Biote Chief Executive Officer Terry Weber. “Our financial performance reflected successful execution of our growth strategy, as we further built our sales team and practitioner network in both existing and new geographic markets. Consumers increasingly seek treatment for many age-related symptoms often caused by hormonal imbalances, and the effectiveness of the Biote method continues to spur patient demand for the customized therapies offered by Biote-certified providers. As we strive to make the Biote brand synonymous with hormone replacement therapy, we remain dedicated to broadening public awareness by advancing the science and research supporting hormone optimization.”

Ms. Weber continued, “In early January, we successfully completed a secondary offering of Biote Class A common stock, representing an important milestone in our journey as a public company. This transaction not only significantly increased the liquidity of our publicly traded shares, but also broadened institutional ownership of our shares. As a management team, we remain focused on building long-term shareholder value through profitable growth.”

2022 Fourth Quarter Financial Review

Revenue for the fourth quarter of 2022 was $44.5 million, an increase of 18.5% from $37.5 million for the fourth quarter of 2021. The increase was driven by continued growth in both procedures and dietary supplements revenue, despite lingering weather-related impacts in Florida and Puerto Rico.

Gross profit margin for the fourth quarter of 2022 was 65.3% compared to 64.0% for the fourth quarter of 2021. The increase in gross profit margin was primarily due to effective cost management.

Operating income for the fourth quarter of 2022 was $7.3 million, an increase of 23.3% from $5.9 million in the fourth quarter of 2021. The increase in operating income reflected increased profitability on higher sales, partially offset by higher SG&A expense.

Net income for the fourth quarter of 2022 was $12.8 million, or $0.18 per diluted share, compared to net income of $5.5 million for the fourth quarter of 2021. Net income increased due to the improvement in operating income and a favorable impact from transaction-related items, partially offset by increased interest expense. The net change in the fair value adjustments to warrant and earnout liabilities was $7.5 million in the fourth quarter, as compared to no such impact in the fourth quarter of 2021.

Adjusted EBITDA for the fourth quarter of 2022 was $13.1 million compared to $9.4 million for the fourth quarter of 2021. The 40% increase in Adjusted EBITDA was driven by the growth in revenue as well as the positive leverage in our business model that enables profit to grow faster than revenue.³

2022 Full Year Financial Review

Revenue for 2022 was $165.0 million, an increase of 18.3% from $139.4 million in 2021. The increase was driven by continued growth in both procedures and dietary supplements revenue.

Gross profit margin for 2022 was 66.9% compared to 65.0% for 2021. The increase in gross profit margin was primarily due to a more favorable product mix.

Operating loss for 2022 was $(60.7) million, compared to operating income of $34.6 million for 2021. Operating loss in 2022 reflected the impact of $21.6 million in transaction-related costs and $82.2 million in stock compensation expense. Excluding these costs, operating income would have been $43.1 million in 2022.

Net income for 2022 was $1.3 million, or a loss of $0.12 per diluted share, compared to net income of $32.6 million in the fourth quarter of 2021.

Adjusted EBITDA for 2022 was $50.1 million compared to $40.2 million for 2021. The 24.6% increase in Adjusted EBITDA was primarily driven by the growth in revenue and the positive operating leverage in our business model.⁴

2023 Financial Outlook

“Biote’s annuity-like business model provides good visibility into our projected financial performance. In 2023 we anticipate continued growth in both revenue and Adjusted EBITDA, as we further build our market presence and practitioner network. We are investing to strengthen our infrastructure and capabilities while continuing to expand our sales team,” said Ms. Weber.

“Our 2023 financial forecast assumes stronger revenue growth and Adjusted EBITDA performance in the second half of the year as we begin to benefit from the contributions of sales personnel added at the end of last year,” concluded Ms. Weber.

($ in millions)	2023 Guidance Range
Revenue	$190-$200
Adjusted EBITDA	$56-$60

Conference Call:

Terry Weber, Chief Executive Officer, and the Company’s management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, March 29, 2023. To access the conference call by telephone, please dial (866) 524-3160 (U.S toll-free) or (412) 317-6760 (International). To access a live webcast of the call, interested parties may use the following link: Biote Q4 and Full Year 2022 Earnings Webcast. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, at ir.biote.com, shortly after the event concludes.

Discussion of Non-GAAP Financial Measures

To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a non-GAAP financial measure that it calculates as net income before interest, taxes and depreciation and amortization, further adjusted to exclude stock-based compensation, transaction-related expenses, fair value adjustments to certain equity instruments classified as liabilities and other non-operating costs. Below we have provided a reconciliation of net income (the most directly comparable GAAP financial measure) to Adjusted EBITDA.

We present Adjusted EBITDA because it is a key measure used by our management to evaluate our operating performance, generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management.

Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:

• Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for assets;
• Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and
• Adjusted EBITDA does not reflect tax payments that may represent a reduction in cash available to us.

In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgment by Biote’s management about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including net income and our other GAAP results.

About Biote

Biote is transforming healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $7 billion global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

Forward-Looking Statements

Except for historical information contained herein, this press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “hope,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitive to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the unpredictability of the effects of the COVID-19 pandemic; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including recent bank failures; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Biote’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and other documents filed by Biote from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

Financial Tables

Biote Corp. Consolidated Balance Sheets (In Thousands) (Unaudited)
		December 31,				December 31,
			2022				2021
Assets
Current assets:
Cash		$	79,231			$	26,766
Accounts receivable, net			6,948				5,231
Inventory, net			11,183				9,615
Other current assets			3,816				5,473
Total current assets			101,178				47,085
Property and equipment, net			1,504				2,335
Capitalized software, net			5,073				4,554
Operating lease right-of-use assets			2,052				356
Deferred tax asset			1,838				—
Total assets		$	111,645			$	54,330
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable		$	4,112			$	4,349
Accrued expenses			6,274				6,011
Term loan, current			6,250				5,000
Deferred revenue, current			1,965				1,705
Operating lease liabilities, current			165				248
Total current liabilities			18,766				17,313
Term loan, net of current portion			112,086				31,963
Deferred revenue, net of current portion			926				802
Operating lease liabilities, net of current portion			1,927				127
Warrant liability			4,104				—
Earnout liability			32,110				—
Total liabilities			169,919				50,205
Commitments and contingencies (See Note 18)
Stockholders’ Equity (Deficit)
Class A, AA, AAA, and AAAA units, no par value, unlimited units authorized; no and 1,013,197 units issued, no and 982,800 units outstanding as of December 31, 2022 and December 31, 2021, respectively			—				—
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding			—				—
Class A common stock, $0.0001 par value, 600,000,000 shares authorized; 11,242,887 and no shares issued, 9,655,387 and no shares outstanding as of December 31, 2022 and December 31, 2021, respectively			1				—
Class B common stock, $0.0001 par value, 8,000,000 shares authorized; no shares issued or outstanding as of December 31, 2022 and December 31, 2021			—				—
Class V voting stock, $0.0001 par value, 100,000,000 shares authorized; 58,565,824 and no shares issued, 48,565,824 and no shares outstanding as of December 31, 2022 and December 31, 2021, respectively			5				—
Additional paid-in capital			—				—
Retained earnings (Accumulated deficit)			(44,460	)			4,165
Accumulated other comprehensive loss			(5	)			(40	)
biote Corp.’s stockholders’ equity (deficit)			(44,459	)			4,125
Noncontrolling interest			(13,815	)			—
Total stockholders’ equity (deficit)			(58,274	)			4,125
Total liabilities and stockholders’ equity (deficit)		$	111,645			$	54,330

Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited)
		Three Months Ended December 31,								Year Ended December 31,
			2022				2021				2022				2021
Revenue:
Product revenue		$	44,012			$	36,979			$	163,133			$	137,598
Service revenue			473				557				1,824				1,798
Total revenue			44,485				37,536				164,957				139,396
Cost of revenue (excluding depreciation and amortization included in selling, general and administrative, below)
Cost of products			14,599				12,802				51,990				46,298
Cost of services			825				724				2,585				2,519
Cost of revenue			15,424				13,526				54,575				48,817
Commissions			186				449				974				2,056
Marketing			1,276				1,683				4,628				4,908
Selling, general and administrative			20,296				15,953				165,502				49,054
Income (loss) from operations			7,303				5,925				(60,722	)			34,561
Other income (expense), net:
Interest expense			(2,182	)			(372	)			(5,091	)			(1,673	)
Gain from change in fair value of warrant liability			575				—				5,127				—
Gain from change in fair value of earnout liability			6,930				—				61,770				—
Loss from extinguishment of debt			—				—				(445	)			—
Other income			619				4				1,073				17
Total other income (expense), net			5,942				(368	)			62,434				(1,656	)
Income before provision for income taxes			13,245				5,557				1,712				32,905
Income tax expense			436				77				388				286
Net income			12,809				5,480				1,324				32,619
Less: Net income attributable to noncontrolling interest			11,187								2,293
Net income (loss) attributable to biote Corp. stockholders			1,622								(969	)
Other comprehensive income (loss):
Foreign currency translation adjustments			(1	)			(3	)			(1	)			(17	)
Other comprehensive income (loss)			(1	)			(3	)			(1	)			(17	)
Comprehensive income		$	12,808			$	5,477			$	1,323			$	32,602
Net income (loss) per common share
Basic		$	0.19							$	(0.12	)
Diluted		$	0.18							$	(0.12	)
Weighted average common shares outstanding
Basic			8,703,533								8,059,371
Diluted			58,750,051								8,059,371

Biote Corp. Consolidated Statements of Cash Flows (In Thousands) (Unaudited)
		Year Ended December 31,
			2022				2021
Operating Activities
Net income		$	1,324			$	32,619
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization			2,199				1,400
Bad debt expense (recoveries)			(155	)			240
Amortization of debt issuance costs			589				222
Provision for obsolete inventory			140				471
Non-cash lease expense			240				226
Non-cash sponsor share transfers			7,216				—
Non-cash fees under SEPA			119				—
Share-based compensation expense			82,180				—
Gain from change in fair value of warrant liability			(5,127	)			—
Gain from change in fair value of earnout liability			(61,770	)			—
Loss from extinguishment of debt			445				—
Deferred income taxes			(743	)			—
Changes in operating assets and liabilities:
Accounts receivable			(1,562	)			(752	)
Inventory			(1,708	)			(5,762	)
Other current assets			(2,284	)			34
Accounts payable			416				1,605
Deferred revenue			384				(373	)
Accrued expenses			(30,841	)			4,029
Operating lease liabilities			(219	)			(239	)
Net cash (used in) provided by operating activities			(9,157	)			33,720
Investing Activities
Purchases of property and equipment			(333	)			(1,448	)
Purchases of capitalized software			(1,505	)			(2,359	)
Net cash used in investing activities			(1,838	)			(3,807	)
Financing Activities
Proceeds from the Business Combination			12,282				—
Principal repayments on term loan			(4,375	)			(5,000	)
Borrowings on term loan			125,000				—
Extinguishment of Bank of America term loan			(36,250	)			—
Debt issuance costs			(4,036	)			—
Settlement of phantom equity rights			(7,250	)			—
Settlement of RSUs			(424	)			—
Distributions			(12,886	)			(11,402	)
Capitalized transaction costs			(8,341	)			(3,941	)
Proceeds from issuance of shares under SEPA			442				—
SEPA transaction costs			(702	)			—
Net cash provided by (used in) financing activities			63,460				(20,343	)
Effect of exchange rate changes on cash and cash equivalents			—				(12	)
Net increase in cash and cash equivalents			52,465				9,558
Cash and cash equivalents at beginning of period			26,766				17,208
Cash and cash equivalents at end of period		$	79,231			$	26,766
Supplemental Disclosure of Cash Flow Information
Cash paid for interest		$	4,426			$	1,462
Cash paid for income taxes			282				171
Non-cash investing and financing activities
Capital expenditures and capitalized software included in accounts payable		$	49			$	282
Non-cash SEPA transaction costs		$	119			$	—

Biote Corp. Reconciliation of Adjusted EBITDA to Net (Loss) Income (In Thousands) (Unaudited)
		Three Months Ended								Year Ended
		December 31,								December 31,
			2022				2021				2022				2021
Net income		$	12,809			$	5,480			$	1,324			$	32,619
Interest expense			2,182				372				5,091				1,673
Income tax expense			436				77				388				286
Depreciation and amortization			555				413				2,199				1,400
Loss from extinguishment of debt and other non-operating items			(619	)			(4	)			(628	)			(17	)
Share-based compensation expense			2,164				—				82,180				—
Transaction-related expenses			978				1,503				21,627				2,387
Litigation and other			2,118				1,531				4,843				1,869
Gain from change in fair value of warrant liability			(575	)			—				(5,127	)			—
Gain from change in fair value of earnout liability			(6,930	)			—				(61,770	)			—
Adjusted EBITDA		$	13,118			$	9,373			$	50,127			$	40,218

_________________________

^1,2 Please see the “Reconciliations of Adjusted EBITDA” table below for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure, net income, and additional information about Adjusted EBITDA.

³ Please see the “Reconciliations of Adjusted EBITDA” table for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure, net income, and additional information about Adjusted EBITDA.

⁴ Please see the “Reconciliations of Adjusted EBITDA” table for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure, net income, and additional information about Adjusted EBITDA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005857/en/

Investor Relations:

Eric Prouty

AdvisIRy Partners

eric.prouty@advisiry.com

Media:

Press@biote.com

Source: Biote

FAQ

What were Biote's financial results for Q4 2022.

Biote reported Q4 2022 revenue of $44.5 million, a year-over-year increase of 18.5%, with a net income of $12.8 million.

What is Biote's revenue guidance for 2023?

Biote expects revenue in the range of $190-$200 million for 2023.

How much did Biote's Adjusted EBITDA increase in 2022?

Biote's Adjusted EBITDA increased by 24.6% in 2022, reaching $50.1 million.

What factors influenced Biote's operating loss in 2022?

Biote's operating loss of $60.7 million for 2022 was largely due to $21.6 million in transaction-related costs and $82.2 million in stock compensation expenses.

What were Biote's key growth drivers in 2022?

Biote experienced growth in both procedures and dietary supplements revenue, contributing to an overall revenue increase of 18.3% in 2022.